Topics

MD Anderson, Artios Pharma and ShangPharma announce in-licensing agreement for DNA damage response inhibitor

19:00 EST 5 Nov 2019 | AAAS

(University of Texas M. D. Anderson Cancer Center) MD Anderson, Artios and ShangPharma have announced the in-licensing by Artios of a small-molecule ATR inhibitor program, developed jointly by MD Anderson and ShangPharma.

Original Article: MD Anderson, Artios Pharma and ShangPharma announce in-licensing agreement for DNA damage response inhibitor

NEXT ARTICLE

More From BioPortfolio on "MD Anderson, Artios Pharma and ShangPharma announce in-licensing agreement for DNA damage response inhibitor"

Quick Search

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...